Covalent inhibitors of K-Ras G12C

Patent metadata

Field	Value
Publication number	US-9926267-B2
Application number	US-201514933734-A
Country	US
Kind code	B2
Filing date	Nov 5, 2015
Priority date	Mar 15, 2013
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

First claim

The invention claimed is:

1. A compound having the following structure (V):

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
R 1 is aryl or heteroaryl;
R 30a and R 30b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 30a and R 30b join to form a carbocyclic or heterocyclic ring; or R 30a is H, —OH, —NH 2 , —CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 30b joins with R 31b to form a carbocyclic or heterocyclic ring;
R 31a and R 31b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 31a and R 31b join to form a carbocyclic or heterocyclic ring; or R 31a is H, —OH, —NH 2 , —CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 31b joins with R 30b to form a carbocyclic or heterocyclic ring;
R 32a and R 32b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 32a and R 32b join to form a carbocyclic or heterocyclic ring; or R 32a is H, —OH, —NH 2 , —CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 32b joins with R 33b to form a carbocyclic or heterocyclic ring;
R 33a and R 33b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 33a and R 33b join to form a carbocyclic or heterocyclic ring; or R 33a is H, —OH, —NH 2 , —CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 33b joins with R 32b to form a carbocyclic or heterocyclic ring;
L 1 is carbonyl, —NHC(═O)—, alkylene, alkenylene, alkylenecarbonyl or alkenylenecarbonyl;
L 2 is a bond or alkylene;
G 1 , G 2 , G 3 and G 4 are each independently N or CR, where R is H, cyano, halo or C 1 -C 6 alkyl;
n 1 , n 2 , n 3 and n 4 are each independently 1, 2 or 3; and
E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a K-Ras, H-Ras or N-Ras G12C mutant protein.

2. The compound of claim 1 , wherein the compound has the following structure (Va):

wherein:
L 1a is a bond, —NH—, alkylene or alkenylene.

3. The compound of claim 2 , wherein the compound has the following structure (Vb):

wherein:
Q is —C(═O)—, —NR 34 C(═O)—, —S(═O) 2 — or —NR 34 S(═O) 2 —;
R 34 is H, C 1 -C 6 alkyl or hydroxylalkyl;
is a carbon-carbon double bond or a carbon-carbon triple bond; and
R 35 and R 36 are each independently H, cyano, C 1 -C 6 alkyl, aminoalkyl, alkylaminoalkyl, or hydroxylalkyl or R 35 and R 36 join to form a carbocyclic or heterocyclic ring when is a double bond; or R 35 is absent and R 36 is H, C 1 -C 6 alkyl, aminoalkyl, alkylaminoalkyl or hydroxylalkyl when is a triple bond.

4. The compound of claim 3 , wherein the compound is selected from the group consisting of (Vc), (Vd), (Ve) and (Vf):

5. The compound of claim 3 , wherein the compound is selected from the group consisting of (Vg), (Vh), (Vi) and (Vj):

6. The compound of claim 3 , wherein the compound is selected from the group consisting of (Vk), (Vl), (Vm), (Vn); (Vo) and (Vp):

7. The compound of claim 1 , wherein R 1 is naphthyl.

8. The compound of claim 1 , wherein R 1 is phenyl.

9. The compound of claim 1 , wherein the aryl is substituted with one or more substituents selected from the group consisting of halo, hydroxyl, cyano, aminocarbonyl, formyl, C 1 -C 6 alkyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxylalkyl, C 1 -C 6 alkoxyalkyl, C 1 -C 6 aminoalkyl, aliphatic heterocyclyl, heteroaryl and aryl.

10. The compound of claim 9 , wherein the substituents are selected from the group consisting of fluoro, chloro, bromo, iodo, hydroxyl, cyano, methyl, ethyl, isopropyl, methylsulfonyl, methoxy, aminocarbonyl, trifluoromethyl, 2,2,2-trifluorethyl, cyclobutyl, cyclopropyl and phenyl, wherein the cyclopropyl and phenyl are optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, halo, hydroxyl and cyano.

11. The compound of claim 10 , wherein the substituents are selected from the group consisting of fluoro, chloro, bromo, iodo, hydroxyl, methyl, ethyl, cyclobutyl and cyclopropyl, wherein the cyclopropyl is optionally substituted with one or more substituents selected from C 1 -C 6 alkyl, halo, hydroxyl and cyano.

12. The compound of claim 11 , wherein the substituents are selected from the group consisting of fluoro, chloro, bromo, hydroxyl and cyclopropyl, wherein the cyclopropyl is optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, halo, hydroxyl and cyano.

13. The compound of claim 1 , wherein R 1 is selected from the group consisting of:

14. The compound of claim 1 , wherein R 1 is heteroaryl.

15. The compound of claim 14 , wherein the heteroaryl is bicyclic.

16. The compound of claim 15 , wherein the heteroaryl is a fused bicyclic heteroaryl.

17. The compound of claim 14 , wherein the heteroaryl is monocyclic.

18. The compound of claim 14 , wherein the heteroaryl comprises nitrogen, sulfur or a combination thereof.

19. The compound of claim 14 , wherein the heteroaryl is selected from the group consisting of dihydroquinoxalinyl, indoleyl, benzoimidazolyl, pyridinyl and thiazolyl.

20. The compound of claim 14 , wherein the heteroaryl is unsubstituted.

21. The compound of claim 14 , wherein the heteroaryl is substituted with one or more substituents.

22. The compound of claim 21 , wherein the substituents are selected from the group consisting of C 1 -C 6 alkyl, halo and oxo.

23. The compound of claim 22 , wherein the substituents are selected from the group consisting of ethyl and chloro.

24. The

Assignees

• Araxes Pharma Llc

Inventors

• Ren Pingda
• Liu Yi
• Li Liansheng
• Feng Jun
• Wu Tao

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D211/60

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D205/04 Primary

  having no double bonds between ring members or between ring members and non-ring members · CPC title